The Human Fibrinogen-like protein 1 (FGL1) ELISA Kit quantifies FGL1 in human serum, plasma, or tissue homogenates. It is not intended for diagnostic use. This assay kit was designed and optimized for cardiovascular research use in humans. The kit has undergone rigorous quality control in multiple parameters, including sensitivity, specificity, precision, linearity, recovery, and inter-batch difference. Refer to the product instructions for more details.
This assay employs the quantitative sandwich enzyme immunoassay technique, in which FGL1 in the samples or standards are sandwiched between pre-coated FGL1 antibody and Biotin-conjugated FGL1 antibody. HRP-avidin is then added into the wells. Following a wash to remove any unbound reagent, the TMB substrate solution is added to the wells and color develops in proportion to the amount of FGL1 bound in the initial step. The color development is stopped upon adding the stop solution, and the intensity of the color is measured at 450 nm via a microplate reader. The levels of FGL1 in the samples can be determined by referring to the O.D. (optical density) of the samples to the standard curve.
FGL1, also known as FREP1 or hepassocin, is a novel hepatocyte belonging to the fibrinogen family. It plays an important role in hepatic steatosis, insulin resistance, liver regeneration, and liver protection. FGL1 is normally released by the liver in low levels but by cancer in high levels. FGL1 acts as a major ligand of LAG-3 (Lymphocyte-activation gene 3) that mediates T cell inhibition, so blockade of the FGL1-LAG-3 interaction enhances antitumor immunity.